Abstract
As a cause of death malignant neoplasms come in at the second place after cardiovascular disorders. CAR-T (chimeric antigen receptor of T-cells) therapy is an advanced malignant tumor treatment method. The use of CAR-T lymphocytes refers to adoptive immunotherapy. CAR-T technology is based on “extracting” immune cells (T-lymphocytes) and their genetic modification aimed at acquiring antitumor properties and followed by reinfusion. The advantage of CAR-T therapy in comparison to other treatment methods is that for target cell recognition T-lymphocytes are not dependent on major histocompatibility complex class 1 (MHC-I) molecules. The literature data we collected and analyzed show that this is a fundamentally new and effective treatment method of oncohematological diseases including acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin’s lymphomas. Clinical trials proved the advantage of CAR-T therapy in comparison to other treatment methods applied in this field. The analysis of literature showed that CAR-T therapy can be reasonably regarded as one of the advanced opportunities for malignant tumor treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
